Ambrx Biopharma Inc. |
10%+ Owner |
Ordinary Shares |
35.7M |
$330M |
$9.24 |
Feb 23, 2023 |
By Commodore Capital Master LP |
Vera Therapeutics, Inc. |
10%+ Owner |
Class A Common Stock |
4.4M |
$79.2M |
$18.00 |
Jan 10, 2024 |
By Commodore Capital Master LP |
Enliven Therapeutics, Inc. |
10%+ Owner |
Common stock, par value $0.001 per share |
1.45M |
$21.9M |
$15.14 |
Feb 23, 2023 |
By Commodore Capital Master LP |
Satsuma Pharmaceuticals, Inc. |
10%+ Owner |
Common Stock, par value $0.0001 per share |
461K |
$326K |
$0.71 |
Nov 14, 2022 |
By Commodore Capital Master LP |
Vistagen Therapeutics, Inc. |
10%+ Owner |
Pre-Funded Warrants (Right to Buy) |
2.79M |
|
|
Oct 4, 2023 |
By Commodore Capital Master LP |
Vistagen Therapeutics, Inc. |
10%+ Owner |
Tranche 2 Warrants (Right to Buy) |
1.69M |
|
|
Oct 4, 2023 |
By Commodore Capital Master LP |
Vistagen Therapeutics, Inc. |
10%+ Owner |
Tranche 1 Warrants (Right to Buy) |
1.39M |
|
|
Oct 4, 2023 |
By Commodore Capital Master LP |